Leerink Partnrs Reiterates “Outperform” Rating for Pyxis Oncology (NASDAQ:PYXS)
Leerink Partnrs reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2023 earnings at ($0.54) EPS, FY2023 earnings at ($2.05) EPS, Q1 2024 earnings at ($0.32) EPS, Q2 2024 earnings at ($0.31) […]
More Stories
Watchdog Uncovers Massive Fraud, Waste in Obamacare Insurance Tax Credits
By Naveen Athrappully An analysis of the Patient Protection and Affordable Care Act (PPACA), commonly known as Obamacare, has unveiled...
US Investor Home Purchases Stall in 3rd Quarter Amid Falling Flipping, Rental Profits
By Mary Prenon Investor home purchases saw little advancement in the third quarter of this year, with just a 1...
Taiwan Bans Chinese App RedNote Over Cybersecurity Failure
By Lily Zhou Taiwan’s government on Dec. 4 banned Chinese social media app RedNote, citing cybersecurity failure and widespread fraud...
Oversight Committee Probes Alleged Cover-Up of Massive Minnesota Welfare Fraud
By Janice Hisle Citing whistleblowers’ allegations that Minnesota officials covered up or ignored massive welfare fraud, a powerful congressional committee...
US Border Patrol to Charge $5,000 Apprehension Fee for Illegal Border Crossers
By Aldgra Fredly The U.S. Border Patrol announced on Dec. 5 that it will impose a $5,000 apprehension fee on...
Bobby Lee’s Net Worth And His Journey To Success
One of the oldest comedians from the US, Bobby Lee, has spent around 30 years in the field of comedy,...